Promise of factor Xa inhibition in atrial fibrillation

Current Cardiology Reports

Volumn 14, Issue 1, 2012, Pages 70-78

  Al Khatib, Sana M ^a   Alexander, John H ^a   Lopes, Renato D ^a   Mahaffey, Kenneth W ^a   Patel, Manesh R ^a   Granger, Christopher B ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Anticoagulants; Anticoagulation; Apixaban; Atrial fibrillation; Bleeding; Dabigatran; Edoxaban; Factor Xa inhibitors; Risk stratification; Rivaroxaban; Stroke prevention; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; PLACEBO; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; DRUG UTILIZATION; DRUG WITHDRAWAL; DYSPEPSIA; EMBOLISM; EVIDENCE BASED MEDICINE; FOOD; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE;

AGE FACTORS; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FACTOR XA; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; UNITED STATES; WARFARIN;

EID: 84857630013     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-011-0230-1     Document Type: Article

References (51)

1. AD Krahn J Manfreda RB Tate, et al. 1995 The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study Am J Med 98 5 476 484 7733127 10.1016/S0002-9343(99)80348-9 1:STN:280:DyaK2M3ltVyjsw%3D%3D
2. PA Poole-Wilson K Swedberg JG Cleland, et al. 2003 Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial Lancet 362 9377 7 13 12853193 10.1016/S0140-6736(03)13800-7 1:CAS:528:DC%2BD3sXltF2isrs%3D (Pubitemid 36835815)
3. AP Maggioni R Latini PE Carson, et al. 2005 Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT) Am Heart J 149 3 548 557 15864246 10.1016/j.ahj.2004.09.033 1:CAS:528:DC%2BD2MXis1GktLo%3D (Pubitemid 40585420)
4. TJ Wang MG Larson D Levy, et al. 2003 Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study Circulation 107 23 2920 2925 12771006 10.1161/01.CIR.0000072767.89944.6E (Pubitemid 36736633)
5. SN Singh XC Tang BN Singh, et al. 2006 Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy J Am Coll Cardiol 48 4 721 730 16904540 10.1016/j.jacc.2006.03.051 (Pubitemid 44175705)
6. P Dorian W Jung D Newman, et al. 2000 The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy J Am Coll Cardiol 36 4 1303 1309 11028487 10.1016/S0735-1097(00)00886-X 1:STN:280:DC%2BD3cvnslWitQ%3D%3D
7. MK Chung L Shemanski DG Sherman, et al. 2005 Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy J Am Coll Cardiol 46 10 1891 1899 16286177 10.1016/j.jacc.2005. 07.040 (Pubitemid 41579813)
8. VE Hagens AV Ranchor E Van Sonderen, et al. 2004 Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study J Am Coll Cardiol 43 2 241 247 14736444 10.1016/j.jacc.2003.08.037 (Pubitemid 38201151)
9. PA Wolf RD Abbott WB Kannel 1991 Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 8 983 988 1866765 10.1161/01.STR.22.8.983 1:STN:280:DyaK3Mzislektg%3D%3D
10. HJ Lin PA Wolf M Kelly-Hayes, et al. 1996 Stroke severity in atrial fibrillation. The Framingham Study Stroke 27 10 1760 1764 8841325 10.1161/01.STR.27.10.1760 1:STN:280:DyaK28vjvV2qsg%3D%3D (Pubitemid 26332500)
11. EM Hylek AS Go Y Chang, et al. 2003 Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 1019 1026 12968085 10.1056/NEJMoa022913 1:CAS:528:DC%2BD3sXntlagtbY%3D (Pubitemid 37087616)
12. HS Jørgensen H Nakayama J Reith, et al. 1996 Acute stroke with atrial fibrillation. The Copenhagen Stroke Study Stroke 27 1765 1769 8841326 10.1161/01.STR.27.10.1765 (Pubitemid 26332501)
13. V Fuster LE Ryden DS Cannom, et al. 2006 ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) J Am Coll Cardiol 48 4 854 906 16904574 10.1016/j.jacc.2006.07.009 (Pubitemid 44175743)
14. IOM. Initial National Priorities for Comparative Effectiveness Research 2009.
15. ACTIVE Writing Group of the ACTIVE Investigators 2006 Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 1903 1912 10.1016/S0140-6736(06)68845-4 (Pubitemid 43842067)
16. The ACTIVE Investigators 2009 Effect of clopidogrel added to aspirin in patients with atrial fibrillation N Engl J Med 360 2066 2078 10.1056/NEJMoa0901301
17. DR Holmes VY Reddy ZG Turi, et al. 2009 Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial Lancet 374 534 542 19683639 10.1016/S0140-6736(09)61343-X 1:CAS:528:DC%2BD1MXpvFyguro%3D
18. P Petersen G Boysen J Godtfredsen, et al. 1989 Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study Lancet 1 175 179 2563096 10.1016/S0140-6736(89)91200-2 1:STN:280: DyaL1M%2Fps1Wrtw%3D%3D (Pubitemid 19038801)
19. SJ Connolly A Laupacis M Gent, et al. 1991 Canadian Atrial Fibrillation Anticoagulation (CAFA) Study J Am Coll Cardiol 18 349 355 1856403 10.1016/0735-1097(91)90585-W 1:STN:280:DyaK3MzhtV2nuw%3D%3D
20. MD Ezekowitz SL Bridgers KE James, et al. 1992 Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators N Engl J Med 327 1406 1412 1406859 10.1056/NEJM199211123272002 1:STN:280: DyaK3s%2FisVOrtA%3D%3D
21. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990;323:1505-11.
22. Stroke Prevention in Atrial Fibrillation Study 1991 Final results Circulation 84 527 539
23. RG Hart O Benavente R McBride, et al. 1999 Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 492 501 10507957 1:CAS:528:DyaK1MXntVWjtLg%3D (Pubitemid 29482392)
24. RG Hart LA Pearce MI Aguilar 2007 Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 857 867 17577005 (Pubitemid 351650486)
25. AJ Camm P Kirchhof GYH Lip, et al. 2010 Guidelines for the management of atrial fibrillation Eur Heart J 31 2369 2429 20802247 10.1093/eurheartj/ehq278
26. NL Smith BM Psaty CD Furberg, et al. 1999 Temporal trends in the use of anticoagulants among older adults with atrial fibrillation Arch Intern Med 159 1574 1578 10421280 10.1001/archinte.159.14.1574 1:STN:280:DyaK1MzkslKnug%3D%3D (Pubitemid 29340311)
27. RH White MA McBurnie T Manolio, et al. 1999 Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort Am J Med 106 165 171 10230745 10.1016/S0002-9343(98)00389-1 1:STN:280:DyaK1M3ksFOktA%3D%3D (Pubitemid 29115956)
28. RS Stafford DE Singer 1998 Recent national patterns of warfarin use in atrial fibrillation Circulation 97 1231 1233 9570191 1:CAS:528: DyaK1cXivVent70%3D (Pubitemid 28169173)
29. AS Go EM Hylek LH Borowsky, et al. 1999 Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study Ann Intern Med 131 12 927 934 10610643 1:CAS:528:DC%2BD3cXkvVOqtA%3D%3D (Pubitemid 30005032)
30. WL Baker DA Cios SD Sander, et al. 2009 Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States J Manag Care Pharm 15 244 252 19326955
31. IM Ogilvie N Newton SA Welner, et al. 2010 Underuse of oral anticoagulants in atrial fibrillation: a systematic review Am J Med 123 638 645.e4 20609686 10.1016/j.amjmed.2009.11.025 1:CAS:528:DC%2BC3cXotVWqu70%3D
32. MC Fang AS Go Y Chang, et al. 2010 Warfarin discontinuation after starting warfarin for atrial fibrillation Circ Cardiovasc Qual Outcomes 3 624 631 20959565 10.1161/CIRCOUTCOMES.110.937680
33. EM Hylek C Evans-Molina C Shea, et al. 2007 Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation 29 115 2684 2686
34. AJ Rose EM Hylek A Ozonoff, et al. 2010 Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA) J Thromb Haem 8 2182 2191 10.1111/j.1538-7836.2010.03996.x 1:STN:280:DC%2BC3cbktVOqsg%3D%3D
35. WC van Walraven RG Hart GA Wells, et al. 2003 A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin Arch Intern Med 163 936 943 12719203 10.1001/archinte.163.8.936 (Pubitemid 36519739)
36. BF Gage AD Waterman W Shannon, et al. 2001 Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation JAMA 285 2864 2870 11401607 10.1001/jama.285.22.2864 1:STN:280:DC%2BD3MzntFKgsQ%3D%3D (Pubitemid 32537350)
37. Lip GYH, Frison L, Halperin JL, et al. Identifying patients at high risk for stroke despite anticoagulation. A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010;41:00-00.online October 2010.
38. R Pisters DA Lane R Nieuwlaat, et al. 2010 A novel userfriendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey Chest 138 1093 1100 20299623 10.1378/chest.10-0134
39. MC Fang AS Go Y Chang, et al. 2011 A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study J Am Coll Cardiol 58 395 401 21757117 10.1016/j.jacc.2011.03.031
40. BI Eriksson DJ Quinlan JW Eikelboom 2011 Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism Annu Rev Med 62 41 57 21226611 10.1146/annurev-med-062209-095159 1:CAS:528:DC%2BC3MXivVWht78%3D
41. SJ Connolly MD Ezekowitz S Yusuf, et al. 2009 Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139 1151 19717844 10.1056/NEJMoa0905561 1:CAS:528:DC%2BD1MXhtFOjsLnN
42. LS Wann AB Curtis KA Ellenbogen, et al. 2011 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran) Circulation 123 1144 1150 21321155 10.1161/CIR.0b013e31820f14c0
43. SJ Connolly MD Ezekowitz S Yusuf, et al. 2010 Newly identified events in the RE-LY trial N Engl J Med 393 1875 1876 10.1056/NEJMc1007378
44. MP Gulseth J Michaud EA Nutescu 2008 Rivaroxaban: an oral direct inhibitor of factor Xa Am J Health Syst Pharm 65 1520 1529 18693206 10.2146/ajhp070624 1:CAS:528:DC%2BD1cXhtFWhtr7E
45. D Kubitza M Becka W Mueck, et al. 2010 Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor Br J Clin Pharmacol 70 703 712 21039764 10.1111/j.1365-2125. 2010.03753.x 1:CAS:528:DC%2BC3cXhsFWhu7zE
46. MR Patel KW Mahaffey J Garg, et al. 2011 Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 883 891 21830957 10.1056/NEJMoa1009638 1:CAS:528:DC%2BC3MXhtFKhsLnI This was the first study to show that a factor Xa inhibitor (rivaroxaban) offers advantages over warfarin. Compared with warfarin, rivaroxaban was associated with a lower risk of intracranial bleeding and fatal bleeding
47. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011 Aug 28 [Epub ahead of print].
48. SJ Connolly J Eikelboom C Joyner, et al. 2011 AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation N Engl J Med 364 806 817 21309657 10.1056/NEJMoa1007432 1:CAS:528:DC%2BC3MXivV2kurc%3D
49. RD Lopes JH Alexander SM Al-Khatib on behalf of the ARISTOTLE investigators, et al. 2010 Apixaban for stroke prevention in atrial fibrillation (ARISTOTLE) trial: design and rationale Am Heart J 159 331 339 20211292 10.1016/j.ahj.2009.07.035 1:CAS:528:DC%2BC3cXivFWgur8%3D
50. CB Granger JH Alexander JV McMurray, et al. 2011 Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 981 992 21870978 10.1056/NEJMoa1107039 1:CAS:528:DC%2BC3MXhtF2ms7rN This study showed that apixaban, a factor Xa inhibitor, is superior to warfarin in reducing stroke or systemic thromboembolism, reducing the risk of bleeding and improving survival. No other medication has achieved these results in stroke prevention in AF
51. CT Ruff RP Giugliano EM Antman, et al. 2010 Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J 160 635 641 20934556 10.1016/j.ahj.2010.06.042 1:CAS:528:DC%2BC3cXht1Kqtr7L